Pfizer and BioNTech said their Covid-19 vaccine is safe and effective for 12- to 15-year-olds, and the companies plan to push for emergency use authorisation for that age group in the US and Europe.
A phase 3 trial showed 100 per cent efficacy in the prevention of symptomatic Covid-19, and “robust” antibody responses exceeding those reported from vaccine trials involving older individuals aged 16 to 25, the drugmakers said.
The companies aim to receive authorisation in time for children to start getting vaccinated for the next school year, said Albert Bourla, Pfizer’s chief executive.
您已閱讀30%（589字），剩餘70%（1377字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。